A guide to clinical trials disrupted by the coronavirus pandemic
As COVID-19 cases surge, drugmakers are halting studies of drugs for other diseases to limit patient risk and ease pressure on hospitals struggling to keep up.
As COVID-19 cases surge, drugmakers are halting studies of drugs for other diseases to limit patient risk and ease pressure on hospitals struggling to keep up.
